Innovent Biologics, a leading pharmaceutical company, announced the launch of its official Environmental, Social, and Governance (ESG) website. This new platform underscores the company’s firm commitment to sustainable development, corporate responsibility, and ethical business practices, aligning with the United Nations’ Sustainable Development Goals (SDGs).
The ESG website serves as a comprehensive resource showcasing Innovent’s initiatives, policies, and performance across key ESG focus areas. These areas include:
- Excellent Governance:
Innovent emphasizes transparent corporate governance, ethical business conduct, regulatory compliance, efficient operations, and robust risk management as the foundation of its business practices.
- Enjoying Good Health:
Innovent is committed to innovative drug development, building strong portfolios in oncology and general biomedicine, and expanding its global pipeline to include 36 innovative assets. With 10 innovative products launched and 5 included in the National Reimbursement Drug List (NRDL), the company has benefited over 2.5 million patients. Innovent also prioritizes inclusive healthcare through patient assistance programs aimed at improving medicine accessibility and affordability.
- Ensuring High-Quality Products:
The company maintains a robust quality management system that meets global standards throughout its products’ life cycles, supported by 140,000 liters of production capacity. Innovent’s commitment extends to manufacturing excellence, operational efficiency, and a sustainable supply chain, while responsibly protecting patient rights and privacy in marketing efforts.
- Empowering Employees:
Innovent fosters a safe, diverse, fair, inclusive, and respectful work environment, providing opportunities for advancement and professional development. Supported by a comprehensive remuneration system and employee care initiatives, the organisation achieved an employee satisfaction rate of over 98% in 2023, with over 50% of its workforce being self-identified female employees.
- Embracing Ecology:
Innovent leads in green development by optimizing its environmental management system and securing ISO14001 certification for all production sites. In 2023, the company implemented extensive environmental production programs, set climate targets, and proactively established strategies to address climate change.
Dr. Michael Yu, Founder, Chairman and CEO of Innovent, said: “As a world-class biopharmaceutical company, Innovent is committed to integrating ESG principles into our business practices. The launch of our ESG website emphasizes our commitment to transparency, accountability and sustainability. It details our efforts to uphold transparent and responsible governance, build a strong portfolio of oncology and general biomedicine assets, maintain high quality throughout our supply chain, support our employees, and integrate ecological and sustainable practices. We believe that by prioritizing these key ESG areas, we can create long-term value for our stakeholders while contributing to a more sustainable future.”
Among the top players in the biotechnology sector, Innovent has an ESG rating of ‘A’ from Morgan Stanley Capital International (MSCI). With the launch of this new ESG website, it will give stakeholders—investors, partners, staff, customers, and community members—detailed information about the company’s ESG performance, objectives, and progress reports.
